No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.
about
Use of glucagon-like peptide-1 agonists to improve islet graft performanceExenatide extended-release: a once weekly treatment for patients with type 2 diabetes.Incretin-based therapies in prediabetes: Current evidence and future perspectivesThe dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins.Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP.Proglucagon-Derived Peptides Do Not Significantly Affect Acute Exocrine Pancreas in RatsA critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls.Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.Incretin therapy and pancreatic pathologies: background pathology versus drug-induced pathology in rats.Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.Incretins: their physiology and application in the treatment of diabetes mellitus.Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents.An updated review on cancer risk associated with incretin mimetics and enhancers.GLP-1 based therapies: clinical implications for gastroenterologists.Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner.Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway.The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?The bone-preserving effects of exendin-4 in ovariectomized rats.
P2860
Q27013927-29A551CB-D1FD-4287-83A5-962EB3E17E72Q33824522-5675DD5C-7845-45BA-8E55-D7C49170D089Q34699191-AA260BE5-BB85-47CF-9810-511E577534EFQ35022184-BBC8F8DB-F858-4075-88A0-6591E67BB750Q36422653-1A323C15-3CFC-4614-88B5-599166906A7BQ36763274-3570C406-B632-42F6-B29A-B65E5F39EDE9Q36942123-E50A60E3-52A0-4ABB-A315-2F245CAB1FABQ37193295-6E2958D7-86BA-4DA1-ACFC-7E3FE9E2BF93Q37193335-BAB019E3-EFAC-4A38-A27F-895F843E12E7Q37402786-94FE15F3-8EE4-4E73-A744-F6FF52058F81Q37660923-500D3521-4757-4BA4-B719-701CE5A0DE8AQ38179267-C282367B-5911-444F-92FE-5E2C917BB947Q38225693-84B12D9A-EA3A-492D-8BEF-70EB9DA3845BQ38255715-240726CB-276A-4ED5-8591-2C4338DFACF6Q38304318-1975D898-17B0-4162-95EC-E504036DAE9FQ38388920-68CA5131-61BC-456E-B92B-F0B0FC8BCB3AQ38703292-FC67D043-8274-44F4-9CE3-0D442E0F1D39Q38997962-CCE9B4DB-689D-4C1D-BFF7-4F304BE551CDQ39014390-4A9608BD-3B5B-4BAD-AA80-118227C9982FQ45778975-74332CAC-CEA8-46DA-ADB5-6F8963A15A85Q50862636-D98F5EFE-BE9E-41FB-8FA0-AC74422ED595Q51012841-93694BD2-0E2F-4C19-84C4-5EE2F45844D2
P2860
No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.
@en
type
label
No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.
@en
prefLabel
No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.
@en
P2093
P2860
P356
P1476
No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.
@en
P2093
P2860
P304
P356
10.1111/DOM.12040
P577
2012-12-07T00:00:00Z